Aquestive officer exercises warrant for 2,293 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Aquestive Therapeutics, Inc. (AQST) reported that Chief People Officer Peter E. Boyd exercised a Common Stock Purchase Warrant on September 9, 2026 to acquire 2,293 shares of common stock at an exercise price of $0.96 per share, a cash exercise of a warrant issued in June 2022. The corresponding warrant position of 2,293 warrant rights was fully exercised, leaving no remaining warrants from this grant, and Boyd now holds 284,024 shares of Aquestive common stock directly. No Rule 10b5-1 trading plan is reported for these transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| In-the-Money Exercise | Warrant (Right to Buy) | 2,293 | $0.00 | $0.00 |
| In-the-Money Exercise | Common Stock F1 | 2,293 | $0.96 | $2K |
Footnotes (1)
- F1. Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share.
Key Figures
Key Terms
Common Stock Purchase Warrant financial
Securities Purchase Agreement financial
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did AQST report for Chief People Officer Peter E. Boyd?
What derivative security did the AQST insider exercise and what were its key terms?
Was the AQST insider’s September 9, 2026 transaction under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.